Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review

(2012) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

(2012) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1- and OATP1B3-mediated Uptake

(2012) Yoshihisa Shitara et al.   Drug Metabolism and Pharmacokinetics

Repaglinide

(2012) Lesley J. Scott   DRUGS

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

(2012) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes

(2012) Emi Kimoto et al.   MOLECULAR PHARMACEUTICS

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

(2012) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

(2012) Aleksi Tornio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

(2011) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

(2011) B. M. VandenBrink et al.   DRUG METABOLISM AND DISPOSITION

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

(2011) J. Honkalammi et al.   DRUG METABOLISM AND DISPOSITION

pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1

(2011) Manthena V. Varma et al.   MOLECULAR PHARMACEUTICS

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models

(2010) Eleanor J. Guest et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

(2010) Manthena V. S. Varma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins

(2009) Michael J. Knauer et al.   CIRCULATION RESEARCH

Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once-Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers

(2009) Andrej Skerjanec et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

(2008) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

(2008) P. J. Kilford et al.   DRUG METABOLISM AND DISPOSITION

A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

(2008) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

(2008) T. Watanabe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS